Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
889,815
result(s) for
"Skin."
Sort by:
Skin
We expose it, cover it, paint it, tattoo it, scar it, and pierce it. Our intimate connection with the world, skin protects us while advertising our health, our identity, and our individuality. This dazzling synthetic overview is a complete guidebook to the pliable covering that makes us who we are. Skin: A Natural History celebrates the evolution of three unique attributes of human skin: its naked sweatiness, its distinctive sepia rainbow of colors, and its remarkable range of decorations. Jablonski places the rich cultural canvas of skin within its broader biological context for the first time, and the result is a tremendously engaging look at us.
eBook
Skin
Discusses the different layers of skin and each layers function. Also explains how things can go wrong, and offers advice on ways to keep the skin and body healthy.
Book
Living Color
Living Color is the first book to investigate the social history of skin color from prehistory to the present, showing how our body's most visible trait influences our social interactions in profound and complex ways. In a fascinating and wide-ranging discussion, Nina G. Jablonski begins with the biology and evolution of skin pigmentation, explaining how skin color changed as humans moved around the globe. She explores the relationship between melanin pigment and sunlight, and examines the consequences of rapid migrations, vacations, and other lifestyle choices that can create mismatches between our skin color and our environment. Richly illustrated, this book explains why skin color has come to be a biological trait with great social meaning— a product of evolution perceived by culture. It considers how we form impressions of others, how we create and use stereotypes, how negative stereotypes about dark skin developed and have played out through history—including being a basis for the transatlantic slave trade. Offering examples of how attitudes about skin color differ in the U.S., Brazil, India, and South Africa, Jablonski suggests that a knowledge of the evolution and social importance of skin color can help eliminate color-based discrimination and racism.
eBook
Happy in our skin
\"Just savor these bouquets of babies--cocoa-brown, cinnamon, peaches and cream. As they grow, their clever skin does too, enjoying hugs and tickles, protecting them inside and out, and making them one of a kind. Fran Manushkin's rollicking text and Lauren Tobia's delicious illustrations paint a breezy and irresistible picture of the human family--and how wonderful it is to be just who you are.\"--Amazon.com.
Book
Potential of Curcumin in Skin Disorders
Curcumin is a compound isolated from turmeric, a plant known for its medicinal use. Recently, there is a growing interest in the medical community in identifying novel, low-cost, safe molecules that may be used in the treatment of inflammatory and neoplastic diseases. An increasing amount of evidence suggests that curcumin may represent an effective agent in the treatment of several skin conditions. We examined the most relevant in vitro and in vivo studies published to date regarding the use of curcumin in inflammatory, neoplastic, and infectious skin diseases, providing information on its bioavailability and safety profile. Moreover, we performed a computational analysis about curcumin’s interaction towards the major enzymatic targets identified in the literature. Our results suggest that curcumin may represent a low-cost, well-tolerated, effective agent in the treatment of skin diseases. However, bypass of limitations of its in vivo use (low oral bioavailability, metabolism) is essential in order to conduct larger clinical trials that could confirm these observations. The possible use of curcumin in combination with traditional drugs and the formulations of novel delivery systems represent a very promising field for future applicative research.
Journal Article
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Plasmacytoid DCs (pDC) produce large amounts of type I IFN (IFN-I), cytokines convincingly linked to systemic lupus erythematosus (SLE) pathogenesis. BIIB059 is a humanized mAb that binds blood DC antigen 2 (BDCA2), a pDC-specific receptor that inhibits the production of IFN-I and other inflammatory mediators when ligated. A first-in-human study was conducted to assess safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in healthy volunteers (HV) and patients with SLE with active cutaneous disease as well as proof of biological activity and preliminary clinical response in the SLE cohort.
A randomized, double-blind, placebo-controlled clinical trial was conducted in HV (n = 54) and patients with SLE (n = 12). All subjects were monitored for adverse events. Serum BIIB059 concentrations, BDCA2 levels on pDCs, and IFN-responsive biomarkers in whole blood and skin biopsies were measured. Skin disease activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A).
Single doses of BIIB059 were associated with favorable safety and PK profiles. BIIB059 administration led to BDCA2 internalization on pDCs, which correlated with circulating BIIB059 levels. BIIB059 administration in patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
Single doses of BIIB059 were associated with favorable safety and PK/PD profiles and robust target engagement and biological activity, supporting further development of BIIB059 in SLE. The data suggest that targeting pDCs may be beneficial for patients with SLE, especially those with cutaneous manifestations.
ClinicalTrials.gov NCT02106897.
Biogen Inc.
Journal Article
Skin and connective tissue
Examines the skin and connective tissues, looking at the general anatomy, biodynamics, and diseases of each.
Book
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
In patients with surgically resected melanoma, those with
BRAF
mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53% lower risk of 3-year recurrence than those who received placebo.
Journal Article